DelMar Pharmaceuticals (NASDAQ: DMPI) shares are moving 21% higher today on news that the company has Institutional Review Board (IRB) approval to conduct its pivotal phase 3 study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3). IRBs are required under FDA regulations to review all human subject research to guarantee that the rights and welfare of human subjects are protected at all times. The VAL-083 STAR-3 GBM trial and all relevant study related materials were critically examined by the leading independent institutional review board and approved without any modifications. “We are pleased to remain on track to open enrollment in this trial at leading centers in the United States. Based on our research, we believe that VAL-083 offers significant potential as a new therapy for GBM patients who currently have no viable treatment options,” DelMar chairman and CEO Jeffrey Bacha stated in the news release.
To view the full press release, visit: http://nnw.fm/aQZ8o
About DelMar Pharmaceuticals, Inc.
DelMar Pharmaceuticals, Inc. was founded in 2010, driven by the passion of its initiators to develop and commercialize unique new cancer therapies that save and improve lives in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. DelMar’s lead product candidate VAL-083 is currently undergoing clinical trials in the U.S. as a potential new therapy for GBM. VAL-083 has been extensively studied by the U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients. For more information, visit www.delmarpharma.com.
About NetworkNewsBreaks
NetworkNewsBreaks (NNB) provide a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
